Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Featured Articles

Overexpression of Collagen XVIII Is Associated with Poor Outcome and Elevated Levels of Circulating Serum Endostatin in Non–Small Cell Lung Cancer

Toshihiko Iizasa, Hao Chang, Makoto Suzuki, Mizuto Otsuji, Sana Yokoi, Masako Chiyo, Shinichiro Motohashi, Kazuhiro Yasufuku, Yasuo Sekine, Akira Iyoda, Kiyoshi Shibuya, Kenzo Hiroshima and Takehiko Fujisawa
Toshihiko Iizasa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makoto Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mizuto Otsuji
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sana Yokoi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masako Chiyo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinichiro Motohashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhiro Yasufuku
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuo Sekine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Iyoda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kiyoshi Shibuya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenzo Hiroshima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takehiko Fujisawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-04-0443 Published August 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: The aim of this study was to determine whether collagen XVIII expression is correlated with circulating serum endostatin and whether this has any prognostic value in patients with non–small cell lung cancer (NSCLC).

Experimental Design: Serum endostatin levels were measured quantitatively by a competitive enzyme immunoassay, and collagen XVIII expression in tumor tissue was investigated with an immunohistochemical method in a series of 94 patients who underwent surgery for NSCLC.

Results: Sixty cases (63.8%) had positive immunohistochemical staining with anticollagen XVIII polyclonal antibodies, including strongly positive staining in 11 (11.7%) cases. The mean (± SD) serum endostatin level was 41.6 ± 34.4 ng/ml in the patient group and 16.3 ± 10.3 ng/ml in the control group (P < 0.0001). The 11 cases who were strongly collagen XVIII-positive had significantly higher serum endostatin levels than the cases who were negative or weakly positive (P = 0.0297). The 5-year survival rates of negative, weakly positive, and strongly positive patients were 77.8%, 56.9%, and 43.8%, respectively. The cases with strongly positive collagen XVIII expression had a significantly poorer outcome than cases with negative expression (P = 0.0027). A multivariate analysis with Cox proportional hazards model for disease-specific survival revealed that expression of collagen XVIII (strongly positive versus negative; weakly positive versus negative), tumor classification, and regional lymph node classification were independent prognostic factors.

Conclusions: Our results suggest that expression of collagen XVIII in tumor tissue is strongly associated with a poorer outcome in NSCLC and correlates with elevated levels of circulating serum endostatin.

INTRODUCTION

Distant metastasis is the most common cause of death resulting from solid malignant tumors, including non–small cell lung cancer (NSCLC), even if the tumors have been completely excised. NSCLC frequently gives rise to metastatic lesions in the lungs, brain, bones, adrenal glands, liver, and other organs.

Angiogenesis plays an important role in the development of micrometastases through fine regulation of endogenous angiogenic factors and endogenous negative regulators of angiogenesis in endothelial cells (1) . Endostatin, a specific inhibitor of endothelial cell proliferation and angiogenesis, was initially isolated from the conditioned media of a murine hemangioendothelioma cell line; it has a molecular weight of 20 000 and a structure consistent with the COOH-terminal domain of collagen XVIII (2) . Collagen XVIII is an extracellular matrix protein that is a component of vascular and epithelial basement membranes throughout the body (3) . The long form of collagen XVIII is found exclusively in the liver and is expressed at high levels by hepatocytes and in hepatocellular carcinomas (3 , 4) . The biological function of collagen XVIII remains unclear; however, it has recently received much attention because it is an endostatin precursor.

Many studies have shown that the administration of endostatin suppresses the growth of both primary and metastatic lesions in experimental animal models (2 , 5, 6, 7, 8, 9, 10) . Dhar et al. (11) reported that serum endostatin levels are inversely correlated with angiogenesis. Some reports have also demonstrated a correlation between the development of metastatic lesions and serum endostatin concentration in human malignancies (12, 13, 14) . To date, no reports have demonstrated a link between overexpression of endostatin in tumor tissue and tumor recurrence after surgery.

In this study, we attempted to clarify the significance of endostatin and collagen XVIII expression in angiogenesis in metastatic lesions of NSCLC patients. We investigated the relationships among circulating serum endostatin, expression of the endostatin precursor collagen XVIII in tumor samples, and various clinical features in NSCLC patients. In addition, we assessed whether serum endostatin and collagen XVIII expression influence tumor recurrence and/or prognosis in NSCLC.

MATERIALS AND METHODS

Patient Plasma and Tumor Tissue Samples.

The study group consisted of 94 patients with NSCLC (69 males and 25 females) who underwent surgery at Chiba University Hospital between 1997 and 2000 with suitable preoperative eligible criteria as described previously (14) . The patients ranged in age from 40 to 83 years (mean ± SD, 64.4 ± 10.0 years). NSCLC was diagnosed histologically in surgically excised tissues. Blood samples were drawn before surgery. Histological types included 64 adenocarcinomas, 28 squamous cell carcinomas, and 2 large cell carcinomas. Pathology staging revealed 40 patients with stage IA or IB disease, 14 patients with stage IIA or IIB disease, 34 patients with stage IIIA or stage IIIB disease, and 6 patients with stage IV disease (see Table 1⇓ ). All cases underwent complete resection with 93 lobectomies and 1 segmentectomy. None of the patients received treatment for NSCLC before surgery. For the first year after surgery, patients were followed every month, then every 3 months from 2 to 5 years, and every 6 months thereafter. Informed consent was obtained from all patients, and the study was approved by the institutional ethics board. Classification of histological type, pathological stage, and tumor-node-metastasis (TNM) classification was performed according to the criteria of the American Joint Committee on Cancer, the staging committees of the International Union against Cancer (15) , and the General Rules for Clinical and Pathological Recording of Lung Cancer described by the Japan Lung Cancer Society (16) . As a control, endostatin serum concentrations were measured in healthy volunteers (n = 16).

View this table:
  • View inline
  • View popup
Table 1

Prognostic variables, 5-year survival, and univariate survival rate analyses (log-rank test)

Competitive Enzyme Immunoassay and Immunohistochemistry.

Serum endostatin levels were measured with a competitive enzyme immunoassay kit (ACCUCYTE Human Endostatin kit; Cytimmune Science, Inc., College Park, MD) as described previously (14) . The minimum detectable endostatin level was 1.95 ng/ml.

Expression of collagen XVIII was confirmed immunohistochemically in 94 patient tumor samples to clarify the localization of expression as described previously (17) . Formalin-fixed, paraffin-embedded, 4-μm sections on silanized slides (Dako, Glostrup, Denmark) were treated with 3% hydrogen peroxide in PBS [0.01 m sodium phosphate (pH 7.2), 0.15 m NaCl] to block endogenous peroxidase and normal rabbit serum to block nonspecific binding sites and were incubated overnight at 4°C with the primary antibody. Immunohistochemical staining was performed with the streptavidin-biotin technique (Histofine kit; Nichirei, Tokyo, Japan) with anticollagen XVIII polyclonal antibodies that have been established to two polypeptides of collagen XVIII (134–150 and 503–518) according to the manufacturer’s instructions (IBL Co., Ltd., Gunma, Japan). The specificity of these antibodies to NSCLC has been confirmed previously with Western blotting (18) . Peroxidase activity was measured with 3,3′-diaminobenzidine. The primary antibody was absent in negative controls. Sections were counterstained with hematoxylin. Without having any previous knowledge of each patient’s clinical and pathological data, all slides were evaluated independently by two pathologists (A. I., K. H.). A score was established corresponding to the sum of (I) the percentage of positive cells (0, negative; 1, <25% positive cells; 2, 26–50% positive cells; and 3, >50% positive cells) and (II) the staining intensity (0, negative; 1, weak; 2, moderate; and 3, high). The maximum sum of (I) + (II) was 6. Scores between 0 and 2 were regarded as negative, scores of 3 and 4 as positive, and scores between 5 and 6 as strongly positive.

Statistical Analysis and Survival.

We used the Mann–Whitney test to perform statistical analyses of serum endostatin levels in each group. The end point was survival time until death from the primary lung cancer, calculated as the time from the date of surgery to the date of death. The cause of death was confirmed by telephone interview with the doctor who monitored the patient. Cause of death was classified as primary lung cancer-related if the patient had a recurrence of the primary lung cancer at the time of death (distant metastasis, local recurrence, or both), excluding death due to respiratory disease, cardiac disease, brain vascular disease, second malignancy, or others. In this study, we analyzed disease-specific survival from the primary lung cancer by censoring patients with nonprimary lung cancer-related disease at the date of death. Disease-specific survival curves were plotted using the Kaplan–Meier method, and the log-rank test was used to assess the statistical significance of differences between groups. We assessed the simultaneous contribution of each covariate in the multivariate analysis, using Cox’s proportional hazards model for the risk ratio in the SPSS statistical software program package (SPSS version 11.0 for Windows, SPSS Inc., Chicago, IL). We used a probability level of 0.10 as the significance level for adding and deleting a covariable from the model. The correlation between T and N status and staging was evaluated with the Spearman rank correlation coefficient (data not shown); we thus excluded staging, which is well recognized to be strongly associated with survival, as a covariable. P values <0.05 were considered statistically significant.

RESULTS

Immunohistochemical Staining of Tumor Samples with Anticollagen XVIII Antibody and Association between Prognosis and Clinical Variables in 94 NSCLC Patients.

Of 94 patients, 60 (63.8%) had positive immunohistochemical staining for collagen XVIII, including weakly positive staining in 49 (52.1%) cases and strongly positive staining in 11 (11.7%) cases (Fig. 1)⇓ . Tumor classification (P = 0.0015), regional lymph node classification (P < 0.0001), postsurgical stage (P < 0.0001), and immunohistochemical expression of collagen XVIII (P = 0.0108) demonstrated a significant correlation with prognosis, respectively, based on the log-rank test (Table 1)⇓ .

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Immunohistochemical staining of tumor tissue from patient with non-small cell lung cancer for collagen XVIII (original magnification, ×200). A, strongly positive collagen XVIII immunostaining of squamous cell carcinoma; B, negative collagen XVIII immunostaining of squamous cell carcinoma.

Correlation between Serum Endostatin Levels and Collagen XVIII Expression.

The mean serum endostatin level was 41.6 ± 34.4 ng/ml in the patient group and 16.3 ± 10.3 ng/ml in the control group (P < 0.0001, Mann–Whitney test).

The 11 cases with strongly positive immunohistochemical staining for collagen XVIII had a statistically higher serum endostatin concentration than the cases with negative or weakly positive staining (P = 0.0297, Mann-Whitney test; Fig. 2⇓ ).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Concentration of serum endostatin in the groups with strongly positive, weakly positive, and negative anticollagen XVIII immunostaining. The mean (SD) concentration were 39.1 ± 32.1, 38.6 ± 26.4, and 62.7 ± 60.9 ng/ml, respectively. The line inside each box represents the 50th percentile of patients. The bottom and top limits of each box represent the 25th and 75th percentiles, respectively. The bottom whisker represents the 10th percentile, and the top whisker represents the 90th percentile. The • represent outliers.

Association between Disease-Specific Survival and Collagen XVIII Expression.

Cases with negative, weakly positive, or strongly positive collagen XVIII expression had 5-year survival rates of 77.8, 56.9, and 43.8%, respectively. The cases with strongly or weakly positive collagen XVIII expression had a significantly poorer outcome than the cases with negative expression (P = 0.0027, log-rank test; Fig. 3⇓ ).

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Disease-specific survival curves for patients with non-small cell lung cancer (Kaplan–Meier estimates) according to expression of collagen XVIII in tumor tissues (n = 94 patients). Log-rank test: (++) versus (−), P = 0.0027, (+) versus (−), P = 0.0322.

Multivariate Analysis for Disease-Specific Survival.

Multivariate analysis for disease-specific survival was performed according to the Cox proportional hazards model using four variables (tumor classification, regional lymph node classification, immunohistochemical expression of collagen XVIII, and serum endostatin level) that gave P values < 0.1 in the univariate analysis; postsurgical stage was excluded as a factor from multivariate analysis in this study because of its considerable statistical correlation with regional lymph node classification. The multivariate analysis for disease-specific survival revealed three independent prognostic factors: immunohistochemical expression of collagen XVIII (strongly positive versus negative, weakly positive versus negative), tumor classification (T2, T3, and T4 versus T1), and regional lymph node classification (N1, N2, and N3 versus N0; Table 2⇓ ).

View this table:
  • View inline
  • View popup
Table 2

Multivariate analysis of independent prognostic factors (Cox proportional hazards model)

DISCUSSION

In this study, we investigated the immunohistochemical expression of collagen XVIII in excised tumor tissues and preoperative serum endostatin levels in patients with NSCLC. We have demonstrated that expression of collagen XVIII in tumor tissue is strongly associated with a poorer outcome in NSCLC. In addition, we found that strong collagen XVIII expression correlates with elevated levels of circulating serum endostatin.

Collagen XVIII is a proteoglycan containing heparan sulfate side chains (19) . Although it belongs to the multiplexin subfamily (20) , collagen XVIII is better known as a precursor of endostatin, which has been identified as a 20-kDa COOH-terminal fragment of collagen XVIII, obtained from culture supernatant of a hemangioendothelioma cell line (EOMA), that suppresses endothelial cell proliferation and angiogenesis (2) . The mechanism for converting collagen XVIII to endostatin has not been elucidated, but some reports have noted that the ability of EOMA cells to produce endostatin is linked to their production of the cysteine protease cathepsin L and matrix metalloproteinases (21) . Elastase has also been shown to be capable of cleaving endostatin from collagen XVIII (22) . The generation of endostatin or collagen XVIII by human tumors appears to depend on tumor histology. Some reports have demonstrated that endostatin serum levels are elevated in patients with breast cancer, bladder cancer, renal cell carcinoma, endometrial cancer, and soft tissue sarcoma (12 , 23, 24, 25, 26) , whereas other investigators have reported circulating endostatin levels similar to those in healthy controls in patients with head and neck squamous cell carcinoma (27) , squamous cell vulvar carcinoma (28) , and hepatocellular carcinoma (29) . We have previously demonstrated that serum endostatin levels are elevated in patients with NSCLC (14) . In this study, we report a significant correlation between overexpression of collagen XVIII in tumor tissue from NSCLC patients and elevated serum endostatin levels, which suggests that the source of serum endostatin may be partially derived from NSCLC tumor cells.

We used immunohistochemistry to investigate the expression of collagen XVIII in NSCLC tumor samples in an attempt to determine the site of collagen XVIII production. Collagen XVIII is expressed by a wide variety of cells and tissues, from the basement membrane of epithelial tissue to hepatocytes (3) . Guenther et al. (30) used in situ hybridization to demonstrate that collagen XVIII is expressed in colorectal cancer stroma cells and ovarian cancer cells, and other investigators have reported high expression of collagen XVIII mRNA in tumor tissue from hepatocellular carcinomas (4) . However, no reports of collagen XVIII expression in NSCLC have been published. In this study, we showed that collagen XVIII was expressed in 60 of 94 NSCLC cases, including high expression in 11 cases. We also used univariate analysis to demonstrate that collagen XVIII expression is associated with a poorer outcome and multivariate and univariate analysis to show that collagen XVIII expression is an independent prognostic factor. In some patients in whom collagen XVIII was overexpressed, early-stage distant metastases were found shortly after surgery (a representative case is shown in Fig. 1⇓ ). There have been few reports concerning any correlation between expression of endostatin/collagen XVIII and long-term survival. Hata et al. (31) reported that the prognosis of ovarian cancer patients with high endostatin gene expression was significantly worse than that of patients with low endostatin expression. We have demonstrated that collagen XVIII expression in NSCLC may correspond to a poorer prognosis. This is the first report to clarify clinically the hypothesis of Folkman (1) , which states that production of an inhibitor of angiogenesis (in this case, endostatin/collagen XVIII expression) from malignant tumors correlates with the growth of metastatic lesions after surgery (2) .

In conclusion, serum endostatin detected in NSCLC patients partially originates from tumor tissues. Overexpression of collagen XVIII in NSCLC is associated with an earlier recurrence and poorer outcome compared with tumor tissues that do not express collagen XVIII. Further study on the mechanisms of in vivo production and conversion of collagen XVIII to endostatin could help elucidate this aspect of angiogenesis regulation in NSCLC. Finally, these results suggest that collagen XVIII/endostatin may be a novel therapeutic target for the treatment of NSCLC.

Footnotes

  • Grant support: Supported in part by Grant-in-Aid 09671362 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Requests for reprints: Takehiko Fujisawa, MD, Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8670 Japan. Phone: 81-43-222-7171, ext. 5464; Fax: 81-43-226-2172; E-mail: fujisawat{at}faculty.chiba-u.jp

  • Received March 5, 2004.
  • Revision received April 27, 2004.
  • Accepted May 11, 2004.

References

  1. ↵
    Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 333: 1757-63, 1995.
    OpenUrlCrossRefPubMed
  2. ↵
    O’Reilly MS, Boehm T, Shing Y, et al Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-85, 1997.
    OpenUrlCrossRefPubMed
  3. ↵
    Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol, 153: 611-26, 1998.
    OpenUrlCrossRefPubMed
  4. ↵
    Musso O, Rehn M, Theret N, et al Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res, 61: 45-9, 2001.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond), 390: 404-7, 1997.
    OpenUrlCrossRefPubMed
  6. ↵
    Yoon SS, Eto H, Lin CM, et al Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res, 59: 6251-6, 1999.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Blezinger P, Wang J, Gondo M, et al Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol, 17: 343-8, 1999.
    OpenUrlCrossRefPubMed
  8. ↵
    Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA, 97: 4802-7, 2000.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res, 60: 4362-5, 2000.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Boehle AS, Kurdow R, Schulze M, et al Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer, 94: 420-8, 2001.
    OpenUrlCrossRefPubMed
  11. ↵
    Dhar DK, Ono T, Yamanoi A, et al Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer (Phila), 95: 2188-95, 2002.
  12. ↵
    Feldman AL, Alexander HR, Jr, Bartlett DL, et al A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol, 8: 741-5, 2001.
    OpenUrlCrossRefPubMed
  13. ↵
    Feldman AL, Alexander HR, Jr, Yang JC, et al Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer (Phila), 95: 1637-43, 2002.
    OpenUrlCrossRef
  14. ↵
    Suzuki M, Iizasa T, Ko E, et al Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer, 35: 29-34, 2002.
    OpenUrlCrossRefPubMed
  15. ↵
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest, 111: 1710-7, 1997.
    OpenUrlCrossRefPubMed
  16. ↵
    The Japan Lung Cancer Society . Classification of lung cancer, pp. 2-110, Kanehara & Co. Tokyo 2000.
  17. ↵
    Iizasa T, Fujisawa T, Suzuki M, et al Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res, 5: 149-53, 1999.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Chang H, Iizasa T, Shibuya K, et al Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma. Cancer (Phila), 100: 1665-72, 2004.
  19. ↵
    Halfter W, Dong S, Schurer B, Cole GJ. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem, 273: 25404-12, 1998.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Oh SP, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA, 91: 4229-33, 1994.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J, 19: 1187-94, 2000.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res, 59: 6052-6, 1999.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Zhao J, Yan F, Ju H, Tang J, Qin J. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett, 204: 87-95, 2004.
    OpenUrlCrossRefPubMed
  24. ↵
    Guan KP, Ye HY, Yan Z, Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology, 61: 719-23, 2003.
    OpenUrlCrossRefPubMed
  25. ↵
    Shaarawy M, El-Sharkawy SA. Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer. Acta Oncol, 40: 513-8, 2001.
    OpenUrlPubMed
  26. ↵
    Feldman AL, Pak H, Yang JC, Alexander HR, Jr, Libutti SK. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer (Phila), 91: 1525-9, 2001.
  27. ↵
    Homer JJ, Greenman J, Stafford ND. Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol, 27: 32-7, 2002.
    OpenUrlCrossRefPubMed
  28. ↵
    Hefler L, Tempfer C, Kainz C, Obermair A. Serum concentrations of endostatin in patients with vulvar cancer. Gynecol Oncol, 74: 151-2, 1999.
    OpenUrlCrossRefPubMed
  29. ↵
    Yamagata M, Shiratori Y, Dan Y, et al Serum endostatin levels in patients with hepatocellular carcinoma. Ann Oncol, 11: 761-2, 2000.
    OpenUrlFREE Full Text
  30. ↵
    Guenther U, Herbst H, Bauer M, et al Collagen type XVIII/endostatin is differentially expressed in primary and metastatic colorectal cancers and ovarian carcinomas. Br J Cancer, 85: 1540-5, 2001.
    OpenUrlCrossRefPubMed
  31. ↵
    Hata K, Fujiwaki R, Nakayama K, Miyazaki K. Expression of the Endostatin gene in epithelial ovarian cancer. Clin Cancer Res, 7: 2405-9, 2001.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 10 (16)
August 2004
Volume 10, Issue 16
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Overexpression of Collagen XVIII Is Associated with Poor Outcome and Elevated Levels of Circulating Serum Endostatin in Non–Small Cell Lung Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Overexpression of Collagen XVIII Is Associated with Poor Outcome and Elevated Levels of Circulating Serum Endostatin in Non–Small Cell Lung Cancer
Toshihiko Iizasa, Hao Chang, Makoto Suzuki, Mizuto Otsuji, Sana Yokoi, Masako Chiyo, Shinichiro Motohashi, Kazuhiro Yasufuku, Yasuo Sekine, Akira Iyoda, Kiyoshi Shibuya, Kenzo Hiroshima and Takehiko Fujisawa
Clin Cancer Res August 15 2004 (10) (16) 5361-5366; DOI: 10.1158/1078-0432.CCR-04-0443

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Overexpression of Collagen XVIII Is Associated with Poor Outcome and Elevated Levels of Circulating Serum Endostatin in Non–Small Cell Lung Cancer
Toshihiko Iizasa, Hao Chang, Makoto Suzuki, Mizuto Otsuji, Sana Yokoi, Masako Chiyo, Shinichiro Motohashi, Kazuhiro Yasufuku, Yasuo Sekine, Akira Iyoda, Kiyoshi Shibuya, Kenzo Hiroshima and Takehiko Fujisawa
Clin Cancer Res August 15 2004 (10) (16) 5361-5366; DOI: 10.1158/1078-0432.CCR-04-0443
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Featured Articles

  • Differential Effects of Delivery of Omega-3 Fatty Acids to Human Cancer Cells by Low-Density Lipoproteins versus Albumin
  • Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells
  • Functionalization of Tumor Necrosis Factor-α Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window
Show more Featured Articles

Molecular Oncology, Markers, Clinical Correlates

  • Prognostic Impact of Hypoxia-Inducible Factors 1α and 2α in Colorectal Cancer Patients
  • Salivary Transcriptome Diagnostics for Oral Cancer Detection
  • Mitochondrial DNA Quantity Increases with Histopathologic Grade in Premalignant and Malignant Head and Neck Lesions
Show more Molecular Oncology, Markers, Clinical Correlates
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement